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Abstract Abaloparatide is a novel, potent and selective
activator of parathyroid hormone receptor 1 (PTHR1)
under clinical development for the treatment of osteo-
porosis. We assessed the effect of 6 weeks of abaloparatide
on bone mass, microarchitecture, quality and strength in
ovariectomized (OVX) rats. After 8 weeks of post-surgical
bone depletion (baseline), OVX rats (n = 20–21/group)
received daily subcutaneous vehicle (OVX-Veh) or aba-
loparatide at 5 or 20 lg/kg. Sham-operated control rats
(n = 24) received vehicle. Areal bone mineral density
(aBMD) of the lumbar spine (L4), total femur and femur
diaphysis was measured at baseline and after 6 weeks of
treatment. Femur and vertebral bone architecture and
mechanical properties were assessed at the end of the
treatment phase. At baseline, OVX-Veh rats exhibited
significantly lower aBMD relative to Sham controls.
Treatment of OVX rats with abaloparatide at 5 or 20 lg/
kg/day increased aBMD dose-dependently in the lumbar
spine, total femur and femur diaphysis to levels exceeding
OVX-Veh or Sham controls. The abaloparatide 5 and
20 lg/kg groups had improved trabecular microarchitec-
ture relative to OVX vehicle, with trabecular BV/TV
exceeding OVX-Veh control values by 57 and 78 % (re-
spectively) at the lumbar spine, and by 145 and 270 % at
the distal femur. Femur diaphyseal cortical volume and
thickness were significantly greater in the abaloparatide
20 lg/kg group relative to OVX vehicle or Sham controls.
Bone strength parameters of the femur diaphysis, femur
neck and L4 vertebra were significantly improved in the
OVX-ABL groups relative to OVX-Veh controls. Bone
mass–strength relationships and estimated intrinsic strength
properties suggested maintained or improved bone quality
with abaloparatide. These data demonstrate skeletal
restoration via abaloparatide treatment of osteopenic OVX
rats, in association with improved trabecular microarchi-
tecture, cortical geometry and bone strength at sites that
have clinical relevance in patients with osteoporosis.
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Introduction
Osteoporosis is a systemic skeletal disease characterized by
low bone mass and microarchitectural deterioration of bone
tissue with a consequent increase in bone fragility and
susceptibility to fractures at multiple skeletal sites, most
often at the spine, hip or wrist [1]. Osteoporosis is esti-
mated to affect [20 million Americans, with 1.5 million
osteoporotic fractures occurring in the USA every year [2].
As the population ages, the prevalence of osteoporosis and
the incidence of osteoporotic fracture is increasing.
Parathyroid hormone (PTH) and PTH(1-34) (teriparatide)
are the only anabolic agents currently approved for treat-
ment of osteoporosis. PTH is secreted by the parathyroid
glands in response to low plasma calcium and acts directly
on bone and kidneys to restore blood calcium levels [3].
PTH and PTH(1-34) were shown to be safe and effective in
increasing bone mass and reducing fracture risk in
Parts of this work were presented previously and in abstract form at
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postmenopausal women with osteoporosis [4, 5]. The
anabolic mechanism of PTH and PTH(1-34) involves the
stimulation of new bone formation, but this action is typ-
ically coupled by increased bone resorption activity
[3, 6–8], and recent clinical data indicate that this resorp-
tive response may significantly limit bone mineral density
(BMD) gains achieved with intermittent PTH(1-34) ther-
apy, notably at cortical sites [9]. Moreover, increased bone
resorption with PTH(1-34) is associated with and may
contribute to increase serum calcium levels [10, 11].
Signaling mediated via the PTH 1 receptor (PTHR1)
plays an important role in skeletal development and
homeostasis. Although both PTH and PTH-related peptide
(PTHrP) act through the common PTHR1, mounting evi-
dence suggests distinct skeletal roles for PTH and PTHrP.
While both ligands can stimulate bone formation pharma-
cologically, PTHrP is uniquely involved in maintaining
post-natal bone mass. For example, mice genetically defi-
cient in PTHrP develop osteoporosis [12–14], whereas
mice deficient in PTH exhibit increased bone mass that
may be indirectly mediated by a local compensatory
induction of PTHrP [13]. These findings suggest that
PTHrP is a naturally occurring skeletal anabolic agent, the
lack of which is not physiologically compensated by
endogenous PTH [12–16]. Distinct receptor binding prop-
erties may be responsible for the differential effects of PTH
and PTHrP [17–19]. Consistent with the genetic evidence
for PTHrP as an important endogenous anabolic factor, a
pharmacology study in adult ovariectomized (OVX) rats
showed that 6 months of daily administration of native
PTHrP(1-36) markedly enhanced bone mass and biome-
chanical properties [20]. Short-term studies with limited
numbers of human volunteers also indicate that treatment
with native PTHrP(1-36) increased bone formation markers
[21–24] and BMD [24], which has driven interest over the
past several years in testing PTHrP(1-36) as a potential
treatment for osteoporosis. The results of these studies have
been mixed, with some suggesting that intermittent
administration of high-dose native PTHrP(1-36) increases
bone formation without concomitant stimulation of bone
resorption and others reporting measurable stimulation of
bone resorption and significant hypercalcemia [21–24].
Abaloparatide (ABL; previously referred to as BA058)
is a novel 34 amino acid peptide selected for its potent and
selective activation of PTHR1 signaling. Abaloparatide has
41 % homology to PTH(1-34) and 76 % homology to
PTHrP(1-34) and was selected to retain potent bone ana-
bolic activity but with a limited effect on bone resorption
and low calcium-mobilizing potential [25]. In a complete
Phase 2 clinical trial in postmenopausal woman with
osteoporosis, daily subcutaneous injection of abaloparatide
for 24 weeks increased BMD of the lumbar spine, total hip
and femoral neck in a dose-dependent manner, in
association with increased biochemical markers of bone
formation. Moreover, the abaloparatide-induced BMD
increases at the total hip were greater than achieved with
teriparatide treatment [25]. These results are consistent
with the bone anabolic activity and profile of abaloparatide.
The current work represents the first published non-
clinical data on the effects of abaloparatide on bone. This
study assessed the effects of 6-week daily administration of
2 doses levels of abaloparatide on bone in adult osteopenic
OVX rats. The OVX rat model of postmenopausal osteo-
porosis allowed for high-resolution imaging of various
skeletal sites to quantify microarchitectural and geometric
changes in cancellous and cortical bone. Destructive
ex vivo biomechanical testing was also performed to assess
changes in the strength of the femur shaft, femur neck and
lumbar vertebra. Results of the current study indicated a
favorable efficacy and bone safety profile with 6 weeks of
abaloparatide administration, which serves as a foundation




All procedures, protocols and study designs were reviewed,
approved and overseen by the Institutional Animal Care
and Use Committee (IACUC) at Radius Health, Inc. A total
of 93 ten-week-old virgin female Sprague–Dawley rats
(Charles River Laboratories) were housed individually in
ventilated, polycarbonate cages with access to food and
water ad libitum. Their environment was maintained at
18–26 C with 30–70 % relative humidity and a 12-h
light/dark cycle. Animals were observed daily for clinical
signs and weekly for changes in body weight.
Experimental Design
After a 2-week acclimation period, animals were randomly
allocated to ovariectomy or sham surgery groups. At
12 weeks of age, animals were either sham-operated
(Sham) or ovariectomized (OVX) and remained untreated
for 8 weeks (bone depletion period). The osteopenic OVX
rats were then treated for 6 weeks by daily SC injection
with either vehicle (0.9 % NaCl; OVX-Veh group; n = 21)
or abaloparatide at 5 lg/kg (OVX-ABL5; n = 20) or
20 lg/kg (OVX-ABL20; n = 20). Sham rats received SC
vehicle (n = 24). The number of animals per group was
chosen to provide a robust preliminary assessment of bone
safety, based on ex vivo bone strength assessments that
have modest statistical power due to the absence of base-
line control data. The study design is outlined in Table 1.
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Areal BMD (aBMD) of the total femur was measured in all
groups by in vivo dual X-ray absorptiometry (DXA) at the
end of the 8 weeks post-surgical bone depletion period.
These data documented the negative impact of OVX on
BMD and served as pre-treatment baseline values to
evaluate percent change in BMD. aBMD of the total femur,
femur diaphysis and lumbar vertebra was also assessed in
the OVX-Veh, OVX-ABL5 and OVX-ABL20 groups at
the end of the 6-week treatment period to evaluate treat-
ment effects. All DXA measurements were performed by
PixiMus (GE-Lunar Corporation, Fitchburg, WI, USA) on
animals that were anesthetized with isoflurane. Animals
were then euthanized, and the femurs and L4 vertebrae
were collected, wrapped with ethanol-soaked gauze and
frozen at -20 C for high-resolution microcomputed
tomography (lCT) and biomechanical testing. Successful
OVX surgery was confirmed postmortem by assessing
uterine atrophy and the absence of ovaries, and corrobo-
rated by DXA-based analysis of BMD changes, as descri-
bed below.
Microcomputed Tomography (lCT) Measurements
Quantitative lCT (mCT40 lCT scanner, Scanco Medical
AG, Basserdorf, Switzerland) was used ex vivo to assess
trabecular architecture in the fourth lumbar vertebra (L4)
and the distal femoral metaphysis, and cortical bone
geometry at the mid-femoral diaphysis, in accordance with
recently published guidelines [26]. Scanning of trabecular
bone at the distal femoral metaphysis was initiated distally
at the level of the growth plate and extending proximally
250 slices. Evaluations were performed on 150 slices
beginning from approximately 0.2 mm proximal to the
growth plate. The entire L4 vertebra was scanned, and the
trabecular bone between the cranial and caudal growth
plates and the cortex was evaluated. Morphometric
parameters were also evaluated, including bone volume
fraction (BV/TV, %), bone volume (BV, mm3), total vol-
ume (bone plus marrow; TV, mm3), trabecular number
(Tb.N, 1/mm), trabecular thickness (Tb.Th, mm), trabecu-
lar spacing (Tb.Sp, mm), connectivity density (Conn.D,
1/mm3), structural model index (SMI) and bone density
(BD, mg/mm2). At the femoral mid-shaft (cortical bone),
23 transverse CT slices were obtained and used to compute
cortical area (Ct.Ar), total area (Tt.Ar), Ct.Ar/Tt.Ar, mar-
row area (M.Ar) and cortical thickness (Cort.Th, mm).
Biomechanical Testing
All biomechanical tests were performed using an Instron
Mechanical Testing Instrument (Instron 4465 retrofitted to
5500). L4 vertebrae were tested in a destructive biome-
chanical compression test. Fresh-frozen vertebrae were
thawed to room temperature, and the posterior pedicle arch,
spinous process, and cranial and caudal ends were then
removed to obtain a vertebral body specimen with two
parallel surfaces and a height approximately equal to
4 mm. Width in the medial–lateral and anterior–posterior
directions at both the cranial and caudal ends was measured
for the calculation of cross-sectional area. The L4 bodies
were placed between two platens, and a load was applied at
a constant displacement rate of 6 mm/min until failure.
Load–displacement curves were recorded by instrument
software (Bluehill v2.5, Instron). The locations for deter-
mining maximum load at failure, stiffness and energy
absorbed were identified manually from the load–dis-
placement curve and calculated by instrument software
(Bluehill v2.5, Instron). The intrinsic property ultimate
strength was calculated from maximum load (N), cross-
sectional area and height (mm) divided by BV/TV that was
obtained by micro-CT. Prior to biomechanical testing,
peripheral quantitative computed tomography (pQCT) was
performed on the excised right femurs using a Stratec
XCT-RM and associated software (Stratec Medizintechnik
GmbH, Pforzheim, Germany; software version 5.40).
Scans were performed at 50 % of the total femoral length
from the distal end of the femur, corresponding to the mid-
diaphyseal failure site expected for a three-point bending
test. The position was verified using scout views, and one
0.5-mm slice perpendicular to the long axis of the femoral
shaft was acquired. The scans were analyzed using a
threshold for delineation of the external boundary. Axial
area moment of inertia was calculated from the pQCT scan
Table 1 Study design




Sham Vehicle 24 Female
Sprague–Dawley rats
20 weeks
6 weeks daily SC treatment
OVX Vehicle 21
OVX ABL 5 lg/kg 20
OVX ABL 20 lg/kg 20
SC subcutaneous, ABL abaloparatide, Sham sham-operated rats, OVX ovariectomized rats
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data and was used in the calculation of intrinsic strength
parameters of the femoral shaft.
Femurs were then subjected to a destructive three-point
bending test. Each whole right femur was placed on the
lower supports of a three-point bending fixture with the
anterior side facing down. The span between the two lower
supports was set at 14 mm. The upper loading device was
aligned to the center of the femoral shaft, and loading was
applied at a constant displacement rate of 6 mm/min until
failure. The locations for determining maximum load,
stiffness and energy absorbed were identified manually
from the load and displacement curve and values calculated
by instrument software (Bluehill v2.5, Instron). The
intrinsic properties ultimate strength, elastic modulus, and
toughness were calculated from maximum load (N), stiff-
ness (N/mm), energy absorbed (mJ), anterior–posterior
diameter (mm) and moment of inertia (mm4). After three-
point bending, the proximal half of the femur was retrieved
for cantilever compression testing of the femoral neck. The
proximal femur was placed firmly in an anchoring platform
with the greater trochanter lodged into a notch in the
platform. Loading was applied to the femoral head with a
stainless steel probe, parallel to the femoral shaft at a
constant displacement rate of 6 mm/min until failure. The
locations for determining maximum load (N), stiffness (N/
mm) and energy absorbed (mJ) were identified manually
from the load and displacement curve and calculated by
instrument software (Bluehill v2.5, Instron).
Statistical Analysis
Results are expressed as mean and standard deviation. All
statistical analyses were performed using ANOVA fol-
lowed by Tukey’s multiple comparison test (GraphPad
Instat, Cary, NC, USA; release 9.1, or GraphPad Prism,
Cary, NC, USA; version 6.07). Linear regression analyses
were conducted with GraphPad Prism, version 6.07.
Results
General Health
OVX was associated with an expected increase in body
weight gain relative to ovary-intact Sham controls (data not
shown). Daily cage-side observations did not identify any
clinical signs of hypercalcemia, and abaloparatide did not
impair body weight gain at either dose. The high dose of
abaloparatide was associated with slightly greater body
weight after 6 weeks of administration (mean ± SD =
414 ± 43 g) relative to OVX-Veh controls (398 ± 42 g).
Abaloparatide was well tolerated at both dose levels for the
duration of the study.
Areal BMD (aBMD)
Total femur aBMD was measured 8 weeks after surgery in
order to assess OVX-induced bone depletion prior to
treatment initiation. At this baseline, total femur aBMD
was decreased by a significant 11 % for all 61 OVX rats
combined (mean ± SD = 0.1845 ± 0.006 gm/cm2) com-
pared to a subset of 10 randomly selected Sham controls
(0.2045 ± 0.009 gm/cm2, P\ 0.001). Total femur aBMD
values in OVX-Veh controls rats remained decreased
compared to intact Sham controls after 6 weeks of treat-
ment (14 % decrease, P\ 0.001) (Fig. 1).
aBMD was also measured at the total femur, femur
diaphysis and lumbar spine in all groups after 6 weeks of
daily treatment with vehicle or abaloparatide. Compared to
pre-treatment baseline values, OVX rats treated with aba-
loparatide at 5 or 20 lg/kg exhibited significant increases
in BMD at the spine (?27 and ?39 %, respectively,
P\ 0.001; Fig. 1), while OVX-Veh controls showed
modest bone loss. Increments in spine aBMD with abalo-
paratide resulted in final spine BMD values that signifi-
cantly exceeded those of OVX-Veh controls (by 28 and
33 %, for OVX-ABL5 and OVX-ABL20 groups, respec-
tively; P\ 0.001, Fig. 1). Furthermore, post-treatment
spine aBMD for the OVX-ABL20 group significantly
exceeds that of ovary-intact Sham control animals
(P\ 0.001 vs. Sham).
Total femur aBMD increased significantly and dose-
dependently in the OVX-ABL5 and OVX-ABL20 groups
relative to baseline (by 21 and 27 %, respectively;
P\ 0.001, Fig. 1). The femur diaphysis exhibited similar
increases in aBMD with abaloparatide relative to baseline
values (Fig. 1). These gains in femur aBMD resulted in
post-treatment aBMD values in the abaloparatide groups
that significantly exceed those of OVX-Veh or Sham
controls (both P\ 0.001, Figs. 1, 2). Collectively, these
data demonstrated marked gains in bone mass in response
to abaloparatide treatment.
Bone Microarchitecture and Volumetric BMD
Consistent with the aBMD measurements, lCT analyses
indicated significant bone deterioration in the OVX-Veh
group relative to Sham controls at the end of the treatment
phase, particularly in trabecular compartments (Fig. 2;
Tables 2, 3). Compared to Sham control rats, L4 of OVX-
Veh rats had 42 % lower trabecular vBMD (Tb.vBMD)
(Table 2, P\ 0.001), 36 % lower trabecular BV/TV
(Tb.BV/TV) (Fig. 2; Table 2, P\ 0.001), significantly
lower values for trabecular number (Tb.N), trabecular
thickness (Tb.Th) and bone volume (BV), and greater
trabecular spacing (Tb.Sp) (Table 2). At the distal femur,
Tb.vBMD was 64 % lower and Tb.BV/TV was 71 % lower
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in OVX-Veh rats relative to Sham rats (Fig. 2; Table 3,
P\ 0.001), and Tb.N, Tb.Th and Conn.D were also lower
in OVX-Veh rats versus Sham controls (Table 3). Cortical
bone was also decreased by OVX, with cortical BV/TV
(Ct.BV/TV) and cortical thickness (Ct.Th) significantly
lower in the femur diaphysis of OVX-Veh rats compared
with Sham controls (Table 3, P\ 0.01 versus Sham).
Six-week treatment with abaloparatide improved vBMD
and bone microarchitectural properties in OVX rats and
fully inhibited OVX-induced bone loss, improving cortical
and trabecular bone parameters to levels at or above the
OVX-Veh and Sham controls. Specifically, L4 from the
OVX-ABL20 group exhibited significantly higher
Tb.vBMD and Tb.BV/TV compared to OVX-Veh animals
Fig. 1 Effect of abaloparatide administration on aBMD in OVX rats.
Upper panels indicate percent change from the pre-treatment baseline
to the end of the 6-week treatment period. Lower panels indicate
absolute aBMD values at the end of the 6-week treatment period.
ABL-5, abaloparatide 5 lg/kg/day; ABL-20, abaloparatide 20 lg/
kg/day. Data represent mean ± SEM, n = 20–24 per treatment
group. *P\ 0.001 versus OVX-Veh. ^P\ 0.001 versus Sham-Veh.
N/A = not applicable due to lack of baseline data for the Sham-Veh
group
Fig. 2 Effect of OVX and abaloparatide administration on trabecular
bone volume fraction (BV/TV) of the L4 vertebral body (left panel)
and the distal femoral metaphysis (right panel) as assessed by lCT.
ABL-5, abaloparatide 5 lg/kg/day; ABL-20, abaloparatide 20 lg/
kg/day. Data are mean ± SEM, n = 20–24 per group. *P\ 0.001
versus OVX-Veh; ^P\ 0.001 versus all other groups; #P\ 0.001 for
ABL-20 versus ABL-5
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(both ?77 %, P\ 0.001; Fig. 2; Table 2) and Sham-Veh
animals (?13 and ?14 %, respectively, P\ 0.001; Fig. 2;
Table 2). The OVX-ABL5 group had 45 % greater
L4 Tb.vBMD and 56 % greater L4 Tb.BV/TV relative to
OVX-Veh treatment (both P\ 0.001; Table 2). Both doses
of abaloparatide were also associated with improved tra-
becular architecture in L4, including increased trabecular
number and thickness, reduced trabecular spacing and
decreased SMI values indicating a more plate-like
arrangement (Table 2).
At the distal femur, the OVX-ABL5 and OVX-ABL 20
groups exhibited Tb.vBMD and Tb.BV/TV values that
were 2.1- to 3.7-fold greater than those of OVX-Veh
controls (P\ 0.001; Fig. 2; Table 3). The distal femur of
both abaloparatide groups also exhibited significant
increases in Tb.Th and Tb.N, along with lower Tb.Sp and
SMI, indicative of a more robust plate-like trabecular
architecture relative to OVX-Veh controls (Table 3).
Evaluation of cortical responses to treatments in the femur
mid-shaft indicated that the OVX-ABL20 group had
Table 2 Effect of OVX and
abaloparatide administration on
trabecular bone in the L4
vertebral body as assessed by
lCT
SHAM vehicle OVX vehicle OVX abaloparatide
5 lg/kg 20 lg/kg
L4 lumbar spine
vBMD (mg/mm3) 560 ± 35* 394 ± 51§ 570 ± 46* 631 ± 50*,§,^
BV/TV (%) 51.5 ± 4.3* 33.0 ± 0.5§ 51.7 ± 4.7* 58.6 ± 5.3*,§,^
Tb.Th (mm) 0.110 ± 0.01* 0.095 ± 0.00§ 0.136 ± 0.01*,§ 0.152 ± 0.01*,§,^
Tb.N (1/mm) 4.87 ± 0.28* 3.62 ± 0.48§ 3.91 ± 0.30*,§ 4.05 ± 0.27*§
Tb.Sp (mm) 0.181 ± 0.01* 0.268 ± 0.05§ 0.219 ± 0.03*,§ 0.201 ± 0.02*,§,^
Conn.D (1/mm3) 75.0 ± 12.9 68.3 ± 11.3 48.0 ± 5.4*,§ 42.1 ± 7.2*,§,^
SMI -1.82 ± 0.74* 0.29 ± 0.43§ -1.33 ± 0.56* -2.23 ± 0.92*,§,^
Data are mean ± SD. n = 20–24 per treatment group
vBMD volumetric bone mineral density, BV bone volume, TV total volume, Tb.Th trabecular thickness,
Tb.N trabecular number, Tb.Sp trabecular separation, Conn.D connectivity density, SMI structure model
index
*P\ 0.05 versus OVX-vehicle group; § P\ 0.05 versus Sham group; ^ P\ 0.05 versus ABL 5 lg/kg
group




diaphysis geometry, as assessed
by lCT
SHAM vehicle OVX vehicle OVX abaloparatide
5 lg/kg 20 lg/kg
Distal femur trabecular bone
vBMD (mg/mm3) 575 ± 79* 199 ± 56§ 421 ± 65*,§ 596 ± 84*,^
BV/TV (%) 53.0 ± 9.2* 15.2 ± 4.5§ 37.2 ± 6.5*,§ 56.2 ± 7.9*,^
Tb.Th (mm) 0.119 ± 0.02* 0.087 ± 0.01§ 0.130 ± 0.01*,§ 0.186 ± 0.03*,§,^
Tb.N (1/mm) 5.74 ± 0.62* 1.66 ± 0.59§ 2.43 ± 0.66*,§ 3.01 ± 0.51*,§,^
Tb.Sp (mm) 0.148 ± 0.03* 0.715 ± 0.28§ 0.494 ± 0.17*,§ 0.399 ± 0.11*,§,^
Conn.D (1/mm3) 115.9 ± 19.5* 42.7 ± 12.8§ 53.1 ± 10.6*,§ 34.7 ± 9.0*,§,^
SMI -1.67 ± 2.31* 1.58 ± 0.17§ -0.39 ± 0.46*,§ -3.26 ± 1.73*,§
Femur diaphysis cortical bone
Ct.Ar/Tt.Ar (%) 67.3 ± 3* 66.3 ± 2§ 66.8 ± 4§ 70.0 ± 3*,§
Ct.Ar (mm2) 3.22 ± 0.17 3.31 ± 0.22 3.60 ± 0.22*,§ 3.67 ± 0.33*,§
Tt.Ar (mm2) 4.80 ± 0.34 4.99 ± 0.36 5.41 ± 0.52*,§ 5.26 ± 0.59§
M.Ar (mm2) 1.57 ± 0.23 1.68 ± 0.20 1.81 ± 0.35 1.59 ± 0.31
Ct.Th (mm) 0.616 ± 0.09* 0.674 ± 0.04§ 0.703 ± 0.04*,§ 0.723 ± 0.05*,§
Data are mean ± SD. n = 20–24 per treatment group
vBMD volumetric bone mineral density, BV bone volume, TV total volume, Tb.Th trabecular thickness,
Tb.N trabecular number, Tb.Sp trabecular separation, Conn.D connectivity density, SMI structure model
index, Ct.Ar cortical area, Tt.Ar total area, M.Ar marrow area
* P\ 0.05 versus OVX-vehicle group; § P\ 0.05 versus Sham group; ^ P\ 0.05 versus ABL 5 lg/kg
group
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significantly greater Ct.Ar/Tt.Ar compared with the OVX-
Veh group (P\ 0.05, Table 3) and Sham controls
(P\ 0.001, Fig. 2; Table 3). Cortical thickness was also
significantly greater in the OVX-ABL20 group relative to
OVX-Veh controls (P\ 0.05, Table 3).
Vertebral and Femoral Bone Strength
OVX resulted in compromised structural strength of L4, as
shown by significantly lower values for maximum load and
energy in OVX-Veh rats compared to Sham controls
(P\ 0.01, Table 4). These bone strength deficits were
fully reversed by abaloparatide, with the OVX-ABL5 and
OVX-ABL20 groups exhibiting maximum load and energy
values significantly exceeding those from the OVX-Veh
and Sham control groups (Table 4). In addition to these
structural strength parameters, vertebral material (i.e., tis-
sue-level) properties were explored by adjusting L4 max-
imum load values for bone volume and for bone density.
The bone volume adjustment was accomplished by divid-
ing L4 maximum load by L4 specimen height, cross-sec-
tional area and micro-CT-derived BV/TV. This estimate of
ultimate strength indicated no significant differences
between any groups (Table 4). Bone density adjustment
was accomplished by dividing L4 maximum load by
micro-CT-derived L4 vBMD. The resulting BMD-adjusted
maximum load values were all statistically similar, with
group mean values (±SEM) of 0.472 ± 0.006 N/g/cm3 for
Sham-Veh, 0.494 ± 0.010 N/g/cm3 for OVX-Veh,
0.559 ± 0.006 N/g/cm3 for OVX-ABL-5 and 0.532 ±
0.006 N/g/cm3 for OVX-ABL-20.
Femur diaphysis three-point bending tests were also
conducted to assess effects of abaloparatide on cortical
bone strength. Consistent with other OVX rat studies [27],
femur diaphysis structural strength parameters tended to be
higher in OVX-Veh rats compared with Sham-Veh rats,
with maximum load and energy values that were 8 and
27 % higher, respectively, than Sham controls (both
P\ 0.05, Table 5). The OVX-ABL5 and OVX-ABL20
groups had significantly improved structural strength of the
femur diaphysis, with maximum load and stiffness values
exceeding those of the OVX-Veh control group by 9–12 %
(\0.05, Table 5). Maximum load, stiffness and energy
values in the abaloparatide groups also significantly
exceeded Sham control group values (all P\ 0.01,
Table 5). Apparent material properties of the femur dia-
physis were modestly influenced by OVX and by abalo-
paratide. Toughness was significantly greater in OVX-Veh
versus Sham controls, and ultimate strength and toughness
were significantly greater in OVX-ABL5 and OVX-ABL20
groups relative to Sham controls (all P\ 0.05, Table 5).
Axial area moment of inertia of the femur diaphysis was
approximately 17 % greater in each OVX-ABL group
relative to sham controls (P\ 0.001, Table 5).
Cantilever compression of the femoral neck showed that
the maximum load tolerated was 7 % lower in OVX-Veh-
treated rats relative to Sham controls (P\ 0.01 versus
Sham, Table 5). The OVX-ABL5 and OVX-ABL20 groups
exhibited increased femur neck strength, with maximum
load (23 and 16 %, respectively, P\ 0.01, Table 5), and
energy (48 %, P\ 0.05) higher than OVX-Veh control.
Bone Mass–Strength Relationships
Relationships between femur diaphysis bone mass and
strength were assessed for by linear regression analysis.
For these analyses the OVX-Veh and Sham-Veh groups
were combined into a single Veh group, and the ABL-5 and
ABL-25 groups were combined into a single ABL group.
Regression lines for the Veh and ABL groups had slopes
that differed significantly from zero (r = 0.38 and 0.42,
respectively, both P\ 0.05) and did not differ from each
other with regard to slope or X or Y intercepts (Fig. 3).
Table 4 Effect of OVX and abaloparatide administration on L4 lumbar spine biomechanical properties
SHAM vehicle OVX vehicle OVX abaloparatide
5 lg/kg 20 lg/kg
Vertebral compression
Maximum load (N) 265 ± 81* 190 ± 71§ 323 ± 68*,§ 336 ± 76*,§
Stiffness (N/mm) 2032 ± 913 1795 ± 894 1872 ± 1037 1845 ± 954
Energy (mJ) 35 ± 16* 22 ± 12§ 62 ± 38*,§ 64 ± 29*,§
Adjusted ult. strength (N/mm2/BV/TV) 65.6 ± 0.7 74.7 ± 1.3 77.9 ± 0.8 70.17 ± 0.7
Data are mean ± SD. n = 20–24 per treatment group
Ult ultimate
* P\ 0.05 versus OVX-vehicle group; § P\ 0.05 versus Sham group
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Discussion
Abaloparatide is a novel peptide activator of the PTH1
receptor signaling pathway that is currently in late-stage
clinical development for the treatment of postmenopausal
women with osteoporosis. The primary goal of osteo-
porosis therapies is to reduce fracture risk by improving
bone strength, and the gold-standard approach for assessing
treatment effects on bone strength is destructive ex vivo
biomechanical testing. The primary objective of this study
was to combine destructive bone strength testing with high-
resolution CT imaging in order to assess the effects of a
6-week regimen of daily abaloparatide injections in adult
OVX rats. We hypothesized that abaloparatide treatment
would reverse bone loss and the deterioration of bone
mechanical properties associated with OVX-induced
osteopenia by promoting gains in bone mass and restora-
tion of bone microarchitecture. The current results, the first
that describe the effects of abaloparatide on bone strength,
indicate that treatment with abaloparatide fully reversed
OVX-induced bone loss and increased bone strength at the
lumbar spine, femur diaphysis and femur neck of OVX
rats. In many cases, bone mass and strength parameters in
the OVX-ABL groups exceeded those of ovary-intact sham
controls, which further highlights the robust efficacy
potential of abaloparatide. These observations of marked
gains in bone mass following treatment with ABL in
osteopenic OVX rats are consistent with the robust BMD
gains seen in a Phase 2 clinical trial with abaloparatide
treatment in postmenopausal woman with osteoporosis
[25].
Abaloparatide administration to osteopenic OVX rats
fully and dose-dependently restored aBMD at the lumbar
spine and femur by 6 weeks, indicating a rapid onset of
effects in cortical and cancellous compartments. Gains in
spine and femur aBMD appear to be mediated primarily by
increases in trabecular and cortical bone volume.
Improvements in cortical bone were evident from increased
aBMD of the mid-femur diaphysis, a purely cortical site,
and from lCT-derived evidence for increases in cortical
bone volume and cortical thickness. Improvements in tra-
becular bone with abaloparatide were revealed by lCT
assessments of L4 and the distal femur metaphysis, which
Table 5 Effect of OVX and
abaloparatide administration on
femur biomechanical properties
SHAM vehicle OVX vehicle OVX abaloparatide
5 lg/kg 20 lg/kg
Femur shaft bending strength
Maximum load (N) 188 ± 14* 204 ± 21§ 223 ± 16*,§ 224 ± 25*,§
Stiffness (N/mm) 771 ± 105 779 ± 133 874 ± 120*,§ 872 ± 127*,§
Energy (mJ) 56 ± 16* 71 ± 19§ 78 ± 17§ 76 ± 20§
Ult. strength (N/mm2) 173 ± 16 177 ± 15 185 ± 18§ 184 ± 19§
Elastic modulus (MPa) 7479 ± 1113 7100 ± 1173 7381 ± 1502 7449 ± 1480
Toughness (MJ/m3) 4.9 ± 1.5* 5.8 ± 1.4§ 6.3 ± 1.3§ 6.0 ± 1.4§
AP diameter (mm) 3.1 ± 0.1 3.1 ± 0.1 3.2 ± 0.1*,§ 3.2 ± 0.2
AAMI (mm4) 5.9 ± 0.7 6.3 ± 0.8 6.9 ± 1.0*,§ 6.9 ± 1.3§
Femur neck cantilever compression strength
Maximum load (N) 100 ± 13 93 ± 15 123 ± 25*,§ 116 ± 20*,§
Stiffness (N/mm) 216 ± 50 189 ± 55 226 ± 65 198 ± 56
Energy (mJ) 31 ± 10 36 ± 11 46 ± 25§ 46 ± 14*,§
Data are mean ± SD. n = 20–24 per treatment group
Ult. ultimate, AP antero-posterior, AAMI axial area moment of inertia
* P\ 0.05 versus OVX-vehicle group; § P\ 0.05 versus Sham group
Fig. 3 Relationship between bone mass and bone strength for the
femur diaphysis. Femur aBMD was assessed at the femur diaphysis
by DXA, and peak load was determined by three-point bending. The
OVX-Veh and Sham-Veh animals were combined into one Veh
group, and the ABL-5 and ABL-20 animals were combined into one
ABL group. For both groups, regression line slopes were significantly
different from zero, and there were no significant differences between
the two groups for slope or for X or Y intercepts
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demonstrated increases in trabecular bone volume and
vBMD, and improved trabecular microarchitecture.
Microarchitectural improvements with abaloparatide
included more numerous and thicker trabeculae, with
reduced spacing and a more plate-like arrangement, each of
which may have contributed to the observed improvements
in vertebral strength. High-dose abaloparatide was also
associated with reduced trabecular connectivity density
values for L4 and the distal femur, and analyses of human
vertebrae suggest that reduced connectivity density may be
associated with greater structural strength [28]. This
seemingly paradoxical relationship does not indicate that
reduced connectivity per se is biomechanically advanta-
geous, but that trabecular structures with more connections
can in some cases be less robust.
Abaloparatide-related gains in bone mass and
improvements in bone microarchitecture parameters were
associated with improved biomechanical parameters. Evi-
dence that BMD gains with abaloparatide leads to
improved bone strength in this preclinical osteoporosis
model extends and complements recently reported clinical
study results where abaloparatide treatment increased
BMD in lumbar spine and total hip in a Phase 2 clinical
study of postmenopausal women with osteoporosis [25].
BMD gains with abaloparatide were rapid in both studies,
reversing the catabolic effects of 8 weeks of OVX-induced
estrogen deficiency within 6 weeks in these rats, and sig-
nificantly increasing lumbar spine and total hip BMD
within 12 weeks in women with osteoporosis [25]. In the
Phase 2 study, BMD gains with abaloparatide were greater
than those observed with teriparatide [rhPTH(1-34)] at both
the 12- and 24-week time points [25]. Data on the effect of
abaloparatide on vertebral and nonvertebral fracture risk
are starting to emerge from a Phase 3 clinical trial [29],
which support the notion that rapid and substantial BMD
gains with abaloparatide are accompanied by substantial
fracture risk reduction.
The effects of abaloparatide treatment were seen in all
regions of the femur, suggesting that the effect on BMD
potentially includes positive effects on both the trabecular
and cortical bone compartments. The pharmacological
mechanisms underlying the BMD effects in the cortical
bone observed with abaloparatide treatment are not entirely
clear. Additional studies will be required to further evalu-
ate the potential effects on both the trabecular and cortical
compartments. The current study provides the first animal
data indicating increased cortical BMD with abaloparatide,
along with increases in trabecular bone microarchitecture
parameters, which were associated with increased bone
strength.
Destructive biomechanical assessments of bone strength
revealed substantial improvements in structural strength in
abaloparatide-treated animals. The effects of abaloparatide
included greater maximum load for L4, the femur diaphysis
and femur neck relative to either OVX-Veh or Sham
controls. It may be noteworthy from a bone quality per-
spective that abaloparatide-induced increments in maxi-
mum load of L4 and the femur diaphysis were well aligned
with the magnitude of gains in bone mass parameters
measured at the same skeletal site, which suggests that
bone matrix that accrues during abaloparatide therapy has
good material properties. Femur BMD values were posi-
tively and similarly correlated with maximum load values
in the two Veh control groups and in the two abaloparatide
groups, suggesting that abaloparatide had no deleterious
effects on bone quality. Bone quality was also assessed by
adjusting structural strength parameters for bone geometry
(femur diaphysis) or for specimen size and bone volume
fraction (L4 vertebral body). By this approach, both aba-
loparatide groups showed similar material properties
compared with OVX-Veh control groups for both skeletal
sites, indicating maintenance of material strength proper-
ties. Based on these findings, it is reasonable to conclude
that increased bone structural strength with abaloparatide is
largely a function of increased bone mass, density and
volume. These initial bone quality assessments will be
followed by additional studies conducted with longer
treatment durations to better assess the impacts of abalo-
paratide on bone strength and bone quality.
The molecular mechanisms by which abaloparatide
exerts its effects on bone are not fully understood but may
be related to confirmation-selective binding to the PTH1
receptor relative to other ligands including PTH and
PTHrP. PTH and PTHrP share some sequence homology
and may have arisen by duplication of a common ancestral
gene, but each plays a distinct role in bone physiology.
PTH, which is secreted by the parathyroid glands, acts in a
classical endocrine manner to promote osteoclastic bone
resorption and calcium mobilization. In contrast, PTHrP
functions as a paracrine regulator of bone formation.
Despite these differences, PTH and PTHrP both increase
intracellular cAMP concentrations by activating the same
PTHR1, a G protein-coupled receptor (GPCR). However,
continuous administration of PTH leads to bone resorption
over formation, whereas continuous PTHrP administration
preferentially stimulates formation [30, 31]. Recent studies
have provided a basis for the divergent actions of PTH and
PTHrP in bone. Specifically, PTHrP activity at PTHR1 is
restricted to the cell surface and yields a brief intracellular
cAMP burst, whereas the receptor conformation associated
with PTH stabilizes its binding to the receptor and its
coupled G protein and moves to internalized compartments
of the cell, leading to persistent cAMP generation
[17, 19, 32, 33]. The significance of ligands that form more
stable complexes and more cAMP responses is a more
catabolic response resulting in elevated blood calcium
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levels [18]. In contrast, ligands such as PTHrP transiently
produce cAMP and mobilize calcium, yet results in greater
anabolic action than PTH. Consistent with these reports, a
recent study evaluated the binding of abaloparatide to two
distinct PTHR1 conformations. The findings suggested that
the enhanced bone anabolic activity seen with abalopara-
tide treatment may arise from a more selective binding to
the R0 PTHR1 than the RG conformation, compared to
PTH (1-34), a long-acting PTH (LA-PTH) analog or
PTHrP [34]. Further studies are required to elucidate the
specific molecular mechanisms of abaloparatide that cause
increased anabolic activity.
This study has several strengths, including a robust
number of animals that provided good statistical power for
the ex vivo assessments of bone architecture and strength.
Many novel bone therapeutics were initially tested in
healthy animals with normal bone mass, whereas this index
pharmacology report for abaloparatide involved ovariec-
tomized rats with established osteopenia, which represents
a reasonably high hurdle for efficacy and proof of concept
for osteoporosis therapy. The study also involved bone
strength assessments at multiple skeletal sites that corre-
spond to areas at increased risk of fracture in post-
menopausal women. The study also has several limitations,
some of which relate to the study goal as an initial phar-
macology assessment, including the use of young growing
animals, the absence of data for histomorphometry and for
bone turnover markers. The study also lacked lCT data on
the proximal femur including the femur neck, and there-
fore, the compartment-specific structural changes associ-
ated with improved femur neck strength in the
abaloparatide groups remain unknown. Future longer-term
studies will address these questions.
In summary, 6 weeks of abaloparatide administration to
OVX osteopenic rats increased bone mass and microar-
chitecture parameters and increased bone strength. Abalo-
paratide was well tolerated, and there was no evidence for
impairment of bone quality or reductions in bone material
properties. The overall data indicate that abaloparatide
administration results in rapid and robust gains in bone
mass and bone strength, and support the continued inves-
tigation of abaloparatide as potential therapy for the
treatment of postmenopausal women with osteoporosis.
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